Focused on developing a pipeline of cancer cell stemness inhibitors that target cancer stem cells (CSCs), Boston Biomedical, Inc. is a biotechnology company spun out of ArQule - itself an SBIR company. Following a working relationship in 2011 with Dainippon Sumitomo Pharma Co., Ltd. involving various rights from Boston Biomedical, Inc. a few months later - in 2012 - the smaller firm was acquired by that corporation and operates as a subsidiary of Dainippon Sumitomo Pharma Co., Ltd. In North America, Boston Biodmecal offers BBI608, a CSC inhibitor in preparation for Phase III trials for patients with colorectal cancer, as well as various Phase Ib and Phase II trials for various solid tumors; and BBI503, a cancer stemness kinase inhibitor in multi-center Phase I trials for patients with various solid tumors. The company also provides ARQ 501, an activated checkpoint therapy (ACTSM)-based small molecule that kills cancer cells through E2F1-mediated DNA damage checkpoint pathway; ARQ 197, a non-ATP competitive selective c-Met inhibitor; ARQ 171, an ACTSM-based E2F1 pathway activator; and ARQ 450RP, a clinical candidate selection stage program on mitotic checkpoint activators. In addition, it offers discovery stage programs, including ArQ800RP, a checkpoint activator; ArQ300RP, a Eg5 inhibitor; and ArQ850RP, a p53 modulator.
